Senores Pharmaceuticals
add_icon

Senores Pharmaceuticals

1,467.30
+4.20
(0.29%)
Market Cap
6,757.44 Cr
PE Ratio
51.48
Volume
1,34,825.00
Day High - Low
1,480.00 - 1,437.10
52W High-Low
1,599.00 - 662.45
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
6,757.44 Cr
EPS
26.39
PE Ratio
51.48
PB Ratio
7.21
Book Value
202.72
EBITDA
168.32
Dividend Yield
0.00 %
Industry
Healthcare
Return on Equity
7.18
Debt to Equity
0.58
Analyst Rating and Forecast
- By Refinitiv from4 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
positive
Senores Pharma clears USFDA inspection at Apnar Pharma2 days ago
Senores Pharmaceuticals completed a USFDA inspection at its subsidiary Apnar Pharma, receiving one minor procedural observation with no GMP-related issues noted.
neutral
Senores Pharmaceuticals Limited has submitted its Business Responsibility and Sustainability Report for FY26 to stock exchanges. The filing details standalone ESG disclosures, including a turnover of ₹10,609 lakh and net worth of ₹74,990 lakh.
neutral
Senores Pharmaceuticals Ltd schedules its 9th AGM for September 25, 2026. The meeting will be held via video conference. E-voting opens on September 22.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,840.00
#1 4,41,477.63
36.91
#1 61,673.90
12.69
#1 11,565
26.53
34.00
9,322.00
2,47,469.81
85.36
11,067.00
13.95
2,568
65.50
63.65
4,965.50
1,88,871.66
86.95
13,886.20
20.34
2,138
3.28
52.16
1,119.10
1,12,607.65
24.28
27,657.90
17.64
5,026
-34.90
45.64
1,366.00
1,10,351.67
33.22
29,044.60
2.24
3,870
-39.18
35.27
1,969.00
1,06,297.76
95.94
6,867.80
22.01
890
#1 123.93
68.28
1,165.50
97,280.68
29.91
35,058.60
3.90
4,158
-69.10
47.72
1,679.80
96,651.98
25.88
34,145.20
5.56
3,503
25.21
57.04
2,095.00
95,790.22
#1 17.09
29,038.90
#1 26.75
5,356
16.00
28.17
2,280.00
94,163.08
44.87
14,636.40
14.85
1,938
29.13
37.57
Growth Rate
Revenue Growth
51.53 %
Net Income Growth
138.70 %
Cash Flow Change
-78.68 %
ROE
-49.15 %
ROCE
1.63 %
EBITDA Margin (Avg.)
-5.13 %

Quarterly Financial Results

Quarterly Financials
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
80
104
80
100
108
126
134
159
178
193
183
Expenses
64
80
59
77
77
95
104
112
121
128
126
EBITDA
16
24
21
23
31
31
30
47
58
65
57
Operating Profit %
19 %
22 %
26 %
21 %
25 %
17 %
20 %
27 %
29 %
27 %
30 %
Depreciation
3
4
4
4
4
5
6
8
8
9
10
Interest
3
3
5
5
6
5
5
6
5
9
7
Profit Before Tax
10
18
14
16
21
21
27
41
45
47
40
Tax
3
3
3
3
4
3
5
11
11
11
9
Net Profit
7
14
11
13
16
18
21
30
34
37
31
EPS in ₹
4.01
8.03
3.39
3.92
5.04
3.81
4.60
6.54
7.29
7.96
6.61

Balance Sheet

Balance Sheet
2022
2023
2024
2025
2026
Total Assets
59
131
622
1,227
1,604
Fixed Assets
7
27
235
301
726
Current Assets
27
51
251
722
812
Capital Work in Progress
8
35
97
173
18
Investments
15
17
0
0
89
Other Assets
29
53
289
754
0
Total Equity & Liabilities
59
131
622
1,227
1,604
Current Liabilities
10
52
248
241
424
Non Current Liabilities
13
34
143
174
215
Total Equity
37
46
232
812
934
Reserve & Surplus
28
36
174
740
888
Share Capital
9
10
31
46
46

Cash Flow

Cash Flow
2022
2023
2024
2025
Net Cash Flow
2
-3
8
98
Investing Activities
-24
-48
-54
-430
Operating Activities
-10
-1
-26
-46
Financing Activities
37
46
87
573

Share Holding

% Holding
Jul 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Jun 2026
Promoter
66.66 %
45.76 %
45.76 %
45.77 %
45.78 %
45.80 %
45.80 %
45.82 %
45.82 %
FIIs
0.00 %
5.51 %
4.25 %
4.17 %
3.67 %
4.28 %
3.35 %
3.64 %
6.62 %
DIIs
0.00 %
18.61 %
11.78 %
9.65 %
9.51 %
8.61 %
9.31 %
9.61 %
9.77 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
27.88 %
28.71 %
31.43 %
31.44 %
31.09 %
31.94 %
31.64 %
29.25 %
Others
33.34 %
2.23 %
9.49 %
8.97 %
9.60 %
10.22 %
9.59 %
9.30 %
8.55 %
No of Share Holders
177
43,707
43,707
37,653
36,389
34,917
34,401
34,126
36,498

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
25 Sept 2026 ANNUAL GENERAL MEETING Annual General Meeting
NA
25 Sept 2026 1,450.20 1,467.30
23 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Jan 2025 530.80 498.50
15 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
15 May 2025 483.75 541.05
23 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Jul 2025 617.55 616.35
18 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
18 Sept 2025 717.85 689.25
06 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Nov 2025 783.35 766.75
20 Jan 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
20 Jan 2026 812.35 806.55
31 Jan 2026 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
31 Jan 2026 845.15 787.35
14 May 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 May 2026 932.45 977.10
27 Jul 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
27 Jul 2026 1,385.90 1,386.15

Announcements

Successful Completion Of USFDA Inspection2 days ago
Reg. 34 (1) Annual Report.4 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication9 days ago
Business Responsibility and Sustainability Reporting (BRSR)10 days ago
Reg. 34 (1) Annual Report.10 days ago
Shareholder Meeting To Be Held On September 25 2026 At 11:30 Am (IST)10 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 27, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 27, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementAug 26, 2026
Appointment of Company Secretary and Compliance OfficerAug 26, 2026
Announcement under Regulation 30 (LODR)-AcquisitionAug 26, 2026
Announcement under Regulation 30 (LODR)-AcquisitionAug 26, 2026
Board Meeting Outcome for Senores Pharmaceuticals Limited Has Informed The Exchange Regarding Outcome Of Board MeetingAug 26, 2026
Intimation For Giving Corporate Guarantee For Credit Facilities Availed By Apnar Pharma Private Limited Subsidiary Of The Company From ICICI Bank LimitedAug 24, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 20, 2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 12, 2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 12, 2026
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportAug 04, 2026
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotAug 04, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 03, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 28, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 27, 2026
Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Raised Through Preferential Issue Of Convertible Equity Warrants For The Quarter Ended On June 30 2026Jul 27, 2026
Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Of Public Issue For Quarter Ended On June 30 2026Jul 27, 2026
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportJul 27, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationJul 27, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 27, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementJul 27, 2026
Financial Results For Quarter Ended June 30 2026Jul 27, 2026
Board Meeting Outcome for Outcome Of Board MeetingJul 27, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 21, 2026
Board Meeting Intimation for Considering And Approving The Unaudited Consolidated And Standalone Financial Results Of The Company For The Quarter Ended June 30 2026 And To Transact Other Business MattersJul 21, 2026
Submission Of Reconciliation Of Share Capital Audit Report For The Quarter Ended June 30 2026Jul 07, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 03, 2026
Shareholder Meeting / Postal Ballot-Notice of Postal BallotJul 02, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 01, 2026
Board Meeting Outcome for Outcome Of Board Meeting Of The Company Held On June 29 2026Jun 29, 2026
Closure of Trading WindowJun 26, 2026
Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015Jun 10, 2026
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerJun 10, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 09, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 04, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 22, 2026
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 21, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 20, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 19, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 15, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 14, 2026
Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Raised Through Preferential Issue Of Convertible Equity Warrants For The Quarter Ended On March 31 2026 May 14, 2026

Technical Indicators

RSI(14)
Neutral
51.88
ATR(14)
Less Volatile
54.61
STOCH(9,6)
Neutral
53.59
STOCH RSI(14)
Neutral
38.77
MACD(12,26)
Bearish
-5.21
ADX(14)
Weak Trend
18.55
UO(9)
Bearish
47.61
ROC(12)
Downtrend And Accelerating
-1.83
WillR(14)
Neutral
-53.21